Coeptis Therapeutics Holdings, Inc.
COEP
$9.48
$0.010.11%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.08M | 2.43M | 1.90M | 2.35M | 2.58M |
| Depreciation & Amortization | 250.00K | -- | 250.00K | -- | 250.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.14M | 2.83M | 2.92M | 3.37M | 7.90M |
| Operating Income | -2.14M | -2.83M | -2.92M | -3.37M | -7.90M |
| Income Before Tax | -1.83M | -3.04M | -3.00M | -3.76M | -6.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.83M | -3.04M | -3.00M | -3.76M | -6.35M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.83M | -3.04M | -3.00M | -3.76M | -6.35M |
| EBIT | -2.14M | -2.83M | -2.92M | -3.37M | -7.90M |
| EBITDA | -1.89M | -2.58M | -2.67M | -3.12M | -7.65M |
| EPS Basic | -0.92 | -1.62 | -1.69 | -2.22 | -4.77 |
| Normalized Basic EPS | -0.56 | -1.01 | -1.06 | -1.39 | -2.98 |
| EPS Diluted | -0.92 | -1.62 | -1.69 | -2.22 | -4.77 |
| Normalized Diluted EPS | -0.56 | -1.01 | -1.06 | -1.39 | -2.98 |
| Average Basic Shares Outstanding | 1.99M | 1.88M | 1.78M | 1.69M | 1.33M |
| Average Diluted Shares Outstanding | 1.99M | 1.88M | 1.78M | 1.69M | 1.33M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
